Table 7.
Number of patients treated with bimatoprost 0·03% for up to 12 months reporting adverse events (incidence of ≥ 2%) in the eye or skin system organ classes (safety population)
| System organ class preferred terma | 0–12 months | 0–6 months | 6–12 months | |||
|---|---|---|---|---|---|---|
| Idiopathic hypotrichosis (n = 118) | Chemotherapy‐induced hypotrichosis (n = 96) | Idiopathic hypotrichosis (n = 118) | Chemotherapy‐induced hypotrichosis (n = 96) | Idiopathic hypotrichosis (n = 106) | Chemotherapy‐induced hypotrichosis (n = 89) | |
| Eye disorders | ||||||
| Conjunctival hyperaemia | 10 (8·5) | 16 (16·7) | 7 (5·9) | 15 (15·6) | 4 (3·8) | 1 (1·1) |
| Punctate keratitis | 3 (2·5) | 9 (9·4) | 3 (2·5) | 8 (8·3) | 0 (0·0) | 1 (1·1) |
| Eyelid pruritus | 7 (5·9) | 3 (3·1) | 6 (5·1) | 3 (3·1) | 1 (0·9) | 1 (1·1) |
| Erythema of eyelid | 6 (5·1) | 3 (3·1) | 2 (1·7) | 1 (1·0) | 5 (4·7) | 2 (2·2) |
| Eye pruritus | 1 (0·8) | 6 (6·3) | 1 (0·8) | 5 (5·2) | 0 (0·0) | 1 (1·1) |
| Skin and subcutaneous disorders | ||||||
| Skin hyperpigmentation | 2 (1·7) | 5 (5·2) | 0 (0·0) | 3 (3·1) | 2 (1·9) | 2 (2·2) |
Values are given as n (%). aWithin each preferred term, a patient was counted once for either treatment period or once for the entire treatment period.